NEW YORK, July 12 — The number that matters: zero genetic tests required.
An artificial intelligence tool developed at New York University has demonstrated it can match or outperform standard genetic tests when it comes to predicting breast cancer recurrence. The bottom line for patients and investors alike is a potential shift away from costly genomic sequencing toward a simpler, faster method that uses nothing more than digital images of tumor tissue and basic clinical data.
Researchers led by Krzysztof J. Geras built the tool to analyze standard pathology slides — the same images already produced during routine cancer diagnosis — and pair them with readily available patient information. No additional biopsies, no genetic sequencing, no weeks-long wait for results.
By the numbers, the implications are straightforward. Genomic tests for breast cancer recurrence can run thousands of dollars and require specialized laboratory processing. The NYU tool, if validated and deployed, would eliminate those costs entirely. For healthcare systems and insurers, the potential savings are significant. For patients, the benefit is faster treatment decisions.
What the study found
The tool has shown it can match or outperform genetic tests in predicting breast cancer recurrence, according to the NYU findings. That is a high bar. Current genomic tests like Oncotype DX are considered the gold standard for determining which early-stage breast cancer patients need chemotherapy and which can safely skip it.
Investors will note that the AI approach does not require any new equipment or specialized lab infrastructure. It works with existing digital pathology systems that are already being adopted in hospitals and cancer centers across the country. That makes it far easier to deploy than genomic tests, which require proprietary technology and certified laboratories.
The figure that matters for adoption timelines, however, is zero — as in zero clinical validation studies completed in diverse patient populations. The NYU team acknowledges that additional studies are needed to confirm the tool’s effectiveness across different healthcare settings and patient demographics.
Next steps for clinical adoption
Geras and his team will likely seek to integrate the tool into clinical workflows, possibly through prospective trials. Those trials would test the AI in real-time decision-making, where doctors use its predictions alongside standard clinical judgment.
The path from research lab to hospital floor is never short. The timeline for adoption depends on regulatory approvals and further research. The Food and Drug Administration will need to review the technology before it can be marketed as a clinical tool. That process typically requires multiple studies demonstrating safety and effectiveness.
If validated, the tool could become a standard part of breast cancer care, helping doctors make more informed decisions about chemotherapy and other treatments. For a disease that affects hundreds of thousands of American women each year, the potential impact is substantial.
The NYU team is now focused on the next phase: confirming that the tool works as well in community hospitals as it does in academic medical centers, and ensuring it performs consistently across racial and ethnic groups that have historically been underrepresented in medical AI research.
Consult your doctor for medical advice.
Sources
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Potential clinical adoption and validation of AI tool”, “description”: “NEW YORK, July 12 — The number that matters: zero genetic tests required. An artificial intelligence tool developed at New York University has demonstrated it…”, “datePublished”: “2026-07-12T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Ava Anderson”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}, “citation”: [{“@type”: “CreativeWork”, “url”: “https://en.wikipedia.org/wiki/Clinical_trial”}]}
